News > Fortune 500
    SAVE   |   EMAIL   |   PRINT   |   RSS  
Anti-HIV gel could protect women
Merck and Bristol-Myers Squibb team up with non-profit IPM to develop microbicide.
November 1, 2005: 8:49 AM EST
By Aaron Smith, CNN/Money staff writer

NEW YORK (CNN/Money) - Two leading drug manufacturers, Merck and Bristol-Myers Squibb, said they are teaming with the International Partnership for Microbicides, a non-profit researcher, to develop a vaginal gel that could prevent HIV, the virus that causes AIDS.

"These historical agreements mark a turning point in the pharmaceutical industry's commitment to develop a safe and effective microbicide to protect women from HIV," Dr. Zeda Rosenberg, chief executive officer of IPM, said in a press release.

Merck (up $0.68 to $28.22, Research) and Bristol-Myers (up $0.03 to $21.17, Research) each signed separate agreements with IPM, allowing the group to distribute the drugs in poor countries without having to pay royalties. The drugs are a new class of antiretrovirals known as entry inhibitors because they prevent HIV from entering host cells, and this is the first time drug makers have licensed such an early-stage drug as a microbicide, according to the companies and IPM.

The microbicides, successfully tested on macaque monkeys, could prevent 2.5 million HIV infections over three years, according to the drug makers and IPM.

__________________

To read about the industry for AIDS drugs, click here.  Top of page

YOUR E-MAIL ALERTS
Follow the news that matters to you. Create your own alert to be notified on topics you're interested in.

Or, visit Popular Alerts for suggestions.
Manage alerts | What is this?